REVERSE-Long COVID-19 With Baricitinib Pilot Study
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This is a pilot study for REVERSE-LC, a phase 3 trial of baricitinib versus placebo in adults
with neurocognitive impairment (a form of Alzheimer's Disease and Related Dementias or ADRD)
or cardiopulmonary symptoms due to Long COVID.
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt University Medical Center
Collaborators:
Emory University University of California, San Francisco University of Minnesota Vanderbilt University Yale University